Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KH617 in advanced solid tumors
NCT05667194Phase 1Recruiting
- Sponsor
- Sichuan Honghe Biotechnology Co., Ltd.
- Start
- Dec 2022
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of KH617 in solid tumor (advanced stage), brain metastases and glioblastoma (GBM) (5 arms), sponsored by Sichuan Honghe Biotechnology Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 90 weeks, Dose-Limiting Toxicity at 90 weeks and 1 more. Started Dec 2022; status: recruiting.
02
Drugs
KH617
03
Conditions
solid tumor (advanced stage)brain metastasesglioblastoma (GBM)
Beyond the preview
Go deeper on NCT05667194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05667194.